tradingkey.logo
搜尋

Glaukos Corp

GKOS
添加自選
153.580USD
+1.525+1.00%
收盤 07-24 16:00美東報價延遲15分鐘
9.02B總市值
虧損本益比TTM

關於 Glaukos Corp 公司

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.

Glaukos Corp簡介

公司代碼GKOS
公司名稱Glaukos Corp
上市日期Jun 25, 2015
CEOBurns (Thomas William)
員工數量995
證券類型Ordinary Share
年結日Jun 25
公司地址1 Glaukos Way
城市ALISO VIEJO
上市交易所NASDAQ OMX NASDAQ Basic NYSE
國家United States of America
郵編92656
電話19493679600
網址https://www.glaukos.com
公司代碼GKOS
上市日期Jun 25, 2015
CEOBurns (Thomas William)

Glaukos Corp公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Thomas William Burns
Mr. Thomas William Burns
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.70M
-0.24%
Mr. David F. Hoffmeister
Mr. David F. Hoffmeister
Independent Director
Independent Director
86.97K
+19.41%
Mr. Mark J. Foley
Mr. Mark J. Foley
Lead Independent Director
Lead Independent Director
59.10K
+3.18%
Ms. Aimee S. Weisner, J.D.
Ms. Aimee S. Weisner, J.D.
Independent Director
Independent Director
51.57K
+3.64%
Dr. Tomas Navratil
Dr. Tomas Navratil
Chief Development Officer
Chief Development Officer
47.84K
-1.50%
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Independent Director
Independent Director
38.60K
+4.87%
Dr. Gilbert H. (Gil) Kliman, M.D.
Dr. Gilbert H. (Gil) Kliman, M.D.
Independent Director
Independent Director
--
--
Mr. Joseph E. Gilliam
Mr. Joseph E. Gilliam
President, Chief Operating Officer
President, Chief Operating Officer
--
--
Dr. Leana S. Wen, M.D.
Dr. Leana S. Wen, M.D.
Independent Director
Independent Director
--
--
Ms. Denice M. Torres, J.D.
Ms. Denice M. Torres, J.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Thomas William Burns
Mr. Thomas William Burns
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.70M
-0.24%
Mr. David F. Hoffmeister
Mr. David F. Hoffmeister
Independent Director
Independent Director
86.97K
+19.41%
Mr. Mark J. Foley
Mr. Mark J. Foley
Lead Independent Director
Lead Independent Director
59.10K
+3.18%
Ms. Aimee S. Weisner, J.D.
Ms. Aimee S. Weisner, J.D.
Independent Director
Independent Director
51.57K
+3.64%
Dr. Tomas Navratil
Dr. Tomas Navratil
Chief Development Officer
Chief Development Officer
47.84K
-1.50%
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Independent Director
Independent Director
38.60K
+4.87%

常見問題

Glaukos Corp的前五大股東是誰?

Glaukos Corp的前五大股東如下:Mr. Thomas William Burns

有多少機構持有Glaukos Corp(GKOS)的股份?

截至2026Q1,共有702家機構持有Glaukos Corp的股份,合計持有的股份價值約為59.35M,占公司總股份的101.04% 。與2025Q4相比,機構持股有所增加,增幅為-2784097.00。

哪個業務部門對Glaukos Corp的收入貢獻最大?

在2026Q1,Glaucoma業務部門對Glaukos Corp的收入貢獻最大,創收421.07M,占總收入的82.98% 。
tradingkey.logo
風險提示:我們的網站和行動應用程式僅提供關於某些投資產品的一般資訊。Finsights 不提供財務建議或對任何投資產品的推薦,且提供此類資訊不應被解釋為 Finsights 提供財務建議或推薦。
投資產品存在重大投資風險,包括可能損失投資的本金,且可能並不適合所有人。投資產品的過去表現並不代表其未來表現。
Finsights 可能允許第三方廣告商或關聯公司在我們的網站或行動應用程式的任何部分放置或投放廣告,並可能根據您與廣告的互動情況獲得報酬。
© 版權所有: FINSIGHTS MEDIA PTE. LTD. 版權所有